Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria boost: can probiotics help ulcerative colitis patients stay in remission?

NCT ID NCT07180186

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether adding probiotics (Bacillus Clausii) to standard mesalamine treatment helps people with ulcerative colitis stay in remission. 70 adults in remission were split into groups: mesalamine alone, probiotics alone, or both. Researchers tracked disease activity, body mass index, and gut bacteria over a year. The goal was to see if probiotics could improve gut health and prevent flare-ups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Probiotics (Bacillus Clausii) and mesalamine
What this could lead to
If probiotics help maintain remission, this could point toward a simple add-on treatment to reduce flare-ups in ulcerative colitis.
What could go wrong
This is a small, completed study in a specific population (Egyptian patients). Results may not apply to other groups, and probiotics are not a replacement for standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

70 people

The number who actually took part.

Started

Jan 2022

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study is a prospective study that will be carried in Tanta University Hospital, Tropical Medicine and Infectious Diseases Department.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients more than 18 years. * Patients with ulcerative colitis in remission as assessed by the clinical activity index (CAI) ≤ 4, endoscopic index (EI) ≤ 4, and no signs of acute inflammation on histological examination. Exclusion Criteria: * Active ulcerative colitis. * Cardiac, hepatic, or renal disease. * Pregnancy. * History of major colonic surgery. * Patients with any malignancy. * Previously taking other probiotics. * Use of steroids within the last 4 weeks before study entry. * Use of antibiotics within the last 2 weeks before study entry

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Microbiota are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Microbiota Probiotic therapy Ulcerative colitis

Contacts and locations

Locations

  • Tanta University

    Tanta, El-Gharbia, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.